8-K: Celularity Appoints Vincent LeVien to Board of Directors and Key Committees

Celularity Inc. announced the appointment of Vincent LeVien as a Class II director, effective June 5, 2025, also assigning him to the Audit and Nominating and Corporate Governance Committees.

Summary

• Celularity Inc. appointed Vincent LeVien as a Class II director to its Board of Directors on June 5, 2025.
• Mr. LeVien will serve until the Annual Meeting of Stockholders in 2026.
• He has also been appointed as a member of the Audit Committee and the Nominating and Corporate Governance Committee.
• Mr. LeVien is currently the Chairman and CEO of I Got a Guy, Inc., a network consulting firm.
• The company stated there are no arrangements or understandings for his selection and no reportable transactions under Item 404(a) of Regulation S-K.

Sentiment

Score: 6

Explanation: The document reports a standard corporate governance event (director appointment) with no immediate positive or negative financial implications. The appointment of a new director to key committees is generally viewed as a neutral to slightly positive development for corporate oversight.

Positives

• Appointment of a new director, Vincent LeVien, potentially bringing fresh perspectives and expertise to the board.
• Mr. LeVien's assignment to both the Audit Committee and the Nominating and Corporate Governance Committee suggests a focus on financial oversight and corporate governance practices.

Future Outlook

The document does not contain specific forward-looking financial statements or guidance, focusing solely on a corporate governance change.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELULARITY INC. Dated: June 6, 2025 By: /s/ Robert J. Hariri Name: Robert J. Hariri, M.D., Ph.D. Title: Chairman and CEO"

Industry Context

The appointment of a new independent director to key committees is a standard corporate governance practice aimed at strengthening board oversight and strategic direction. This aligns with general industry trends emphasizing robust governance structures, particularly in the biotechnology and healthcare sectors where Celularity operates, given the complex regulatory and financial landscapes.

Comparison to Industry Standards

• The appointment of an independent director to the Audit Committee is a standard best practice for public companies, aligning with Nasdaq listing rules and Sarbanes-Oxley Act requirements, which mandate independent directors on audit committees.
• Similarly, appointing an independent director to the Nominating and Corporate Governance Committee is consistent with strong corporate governance frameworks, ensuring objectivity in director nominations and governance policy oversight.
• While no specific comparable companies or projects are mentioned, the structure of Celularity's board and committee appointments appears to follow established governance norms for publicly traded biotechnology firms.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of a new director to key committees can enhance corporate governance and oversight, potentially leading to better long-term decision-making and shareholder value protection.

Next Steps

• Mr. LeVien will serve as a Class II director until the Annual Meeting of Stockholders in 2026.

Key Dates

Recommendation

Keywords

Celularity Inc., CELU, Board of Directors, Director Appointment, Corporate Governance, Audit Committee, Nominating and Corporate Governance Committee, Vincent LeVien, SEC Filing, 8-K